Program Overview
In this module, Perry Shieh, MD, PhD, along with Claudia Chiriboga, MD, MPH, course chair, will review strategies for the long-term treatment of SMA to optimize patient outcomes. The expert faculty will discuss long-term efficacy and safety data in order to develop effective SMA patient management strategies with the interprofessional team and identify available resources for optimal care while the health system is disrupted by COVID-19. Upon completion of this 30-minute module, clinicians will gain insight into the management strategies for patients with SMA, incorporating the interprofessional team.
Target Audience
Neurologists, pediatricians, geneticists, primary care physicians, nurses, NPs, PAs, pharmacists, and other healthcare providers involved in the management of patients with SMA
Learning Objective
- Review long-term efficacy and safety data to develop effective SMA patient management strategies with the interprofessional team and identify available resources for optimal care while the health system is disrupted by COVID-19
Faculty
Claudia A. Chiriboga, MD, MPH
Professor of Neurology
Columbia University
New York, NY
Perry B. Shieh, MD, PhD
Professor of Neurology
David Geffen School of Medicine
University of California, Los Angeles
Los Angeles, CA
Disclosures of Conflict of Interest
It is the policy of AcademicCME that all faculty, instructors, and planners disclose real or apparent conflicts of interest relating to the topics of this educational activity.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CE activity:
| Faculty | Relationship Identified With: |
| Claudia A. Chiriboga, MD, MPH
|
Consultant/Advisor: AveXis, Inc.; Biogen; Cytokinetics, Inc.; F. Hoffmann-La Roche Ltd.
Grant/Research Support: AveXis, Inc.; Biogen; F. Hoffmann-La Roche Ltd. Speaker’s Bureau: Biogen |
| Perry B. Shieh, MD, PhD
|
Consultant/Advisor: AveXis, Inc.; Biogen; Genentech, USA Inc. Inc.; PTC Therapeutics; Sarepta Pharmaceuticals
Grant/Research Support: AveXis, Inc.; Biogen; Pfizer Inc.; PTC Therapeutics; Sanofi; Sarepta Pharmaceuticals Speaker’s Bureau: Alexion Pharmaceuticals, Inc.; Biogen; CSL Behring; Grifols, S.A. |
Planners and Peer Reviewers
Timothy Hayes, MD, PhD; Kim Cheramie, MSN, RN-BC; Nicole McMenamin and Chelsey Benedek hereby state that they or their spouse/life partner do not have any financial relationships to products or devices with any commercial interests related to the content of this activity of any amount during the past 12 months.
Accreditation Statement
In support of improving patient care, AcademicCME is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. This activity was planned by and for the healthcare team.
Credit Designation Statements
AcademicCME designates this live material for a maximum of 0.50 AMA PRA Category 1 Credits TM.
Participants should claim only the credit commensurate with the extent of their participation in the activity.
Financial Support
This activity has been supported by an independent educational grant from Biogen
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. AcademicCME and Biogen do not recommend the use of any agent outside of the labeled indications.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Method of Participation
In order to claim credit, participants must complete the following:
- Read the learning objectives, accreditation information and faculty disclosures at the beginning of this activity.
- Complete the Pre-Activity Questions
- Read or Review the activity content.
- Complete the Post-Activity Test Questions and Evaluation.
- Learners who receive a grade of 66% or better on the Post-Activity Test Questions and complete the Evaluation will receive appropriate credit as indicated (CME, CNE, and/or CPE credit).
- CPE credit will be posted to the learner’s CPE Monitor profile within 60 days of completion.
- CME and CNE credit will be issued appropriate certificate of completion.
- Others may request a “certificate of completion”.
- Learners should claim only the credit commensurate with the extent of their participation in the activity.
CE Inquiries/Special Needs
For all CE inquiries or special needs, please contact [email protected].
